Significant benefits of pembrolizumab in treating refractory advanced pulmonary sarcomatoid carcinoma: A case report

Figure 4 Tumor changes with pembrolizumab treatment. A: Thyroid gland metastasis before pembrolizumab (orange arrow); B: Thyroid gland metastasis shrank obviously after 2 mo of pembrolizumab; C: Thyroid gland metastasis shrank obviously after 4.5 mo of pembrolizumab; D: Thyroid gland metastasis was still well controlled after 8 mo of pembrolizumab; E: Oropharynx left anterior wall metastasis before pembrolizumab (orange arrow); F: Oropharynx left anterior wall metastasis shrank obviously after 2 mo of pembrolizumab; G: oropharynx left anterior wall metastasis shrank obviously after 4.5 mo of pembrolizumab; H: Oropharynx left anterior wall metastasis was still well controlled after 8 mo of pembrolizumab; I: Left lung metastasis before pembrolizumab (orange arrow); J: Left lung metastasis shrank obviously after 2 mo of pembrolizumab; K: Left lung metastasis shrank obviously after 4.5 mo of pembrolizumab; L: Left lung metastasis was still well controlled after 8 mo of pembrolizumab; M: Right adrenal gland metastasis before pembrolizumab (orange arrow), spleen metastasis before pembrolizumab (white arrow); N: right adrenal gland metastasis shrank after 2 mo of pembrolizumab (orange arrow), spleen metastasis shrank obviously after 2 mo of pembrolizumab; O: right adrenal gland metastasis progressed gradually after 4.5 mo of pembrolizumab (orange arrow), spleen metastasis still shrank obviously after 4.5 mo of pembrolizumab; P: Right adrenal gland metastasis progressed rapidly after 8 mo of pembrolizumab, spleen metastasis was still well controlled after 8 mo of pembrolizumab.